Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the Prescribing and Patient Information for Breastfeeding Mothers NEW HAVEN, Conn. , April 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update

Biohaven Pharmaceutical has a significant portfolio of innovative product candidates across neurological and neuropsychiatric diseases. The company's product, NURTEC ODT, is the first and only therapy approved by FDA to both treat and prevent migraine attacks.

Biohaven Pharmaceutical: Recent Growth Will Continue

Longitudinal medical and prescription claims were used to assess opioid prescriptions and MME's dispensed amongst migraine patients nine months prior to and nine months following Nurtec® ODT initiation.   Among the 14,019 with migraine who used opioids prior to initiating treatment with Nurtec ODT, approximately 41% had no opioid Rx fills in the 9 months following initiation.

Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis

NHF's Veterans/Military Outreach Program aims at raising awareness of migraine in this high-risk population Sponsorship adds to existing Biohaven programs supporting active-duty service members, veterans and their families with migraine NEW HAVEN, Conn., April 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Expands Commitment to Supporting Veterans and Military Through Sole Sponsorship of National Headache Foundation's (NHF) Outreach Program

NEW HAVEN, Conn. , April 1, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal

Migraine patients treated with Nurtec ODT had a reduction in total opioid prescriptions filled after initiation of therapy, according to an analysis of real-world administrative claims Single and multiple daily doses of intranasal zavegepant of up to 40 mg were well tolerated in Phase 1 study Rimegepant, atogepant and monoclonal antibody treatments determined to be effective options for the prevention of migraine when compared vs placebo NEW HAVEN, Conn. , March 31, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases

Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) and its shareholders could be in for a pleasant surprise if the company's failed Alzheimer's drug proves effective in treating a rare disease.

Biohaven Drug Is a Long Shot, But Success Could Boost Shares

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT.

Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod

Biohaven Pharmaceutical Holding's (BHVN) CEO Vlad Coric on Q4 2021 Results - Earnings Call Transcript

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -45.41% and 0.06%, respectively, for the quarter ended December 2021.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates

NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS

Pfizer

NEW HAVEN, Conn. and NEW YORK, Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment

NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb

NEW HAVEN, Conn., Feb. 22, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Earnings Next Week?

NEW HAVEN, Conn., Feb. 16, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022

Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.

Biohaven (BHVN) Migraine Drug Meets Study Goals in China

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine.  The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom, including either nausea, phonophobia, or photophobia at 2-hours following a single oral dose of rimegepant.

Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints

NEW HAVEN, Conn. and NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

NEW YORK, Feb.12, 2022 /PRNewswire/ -- Heating up the runway this winter, Jessica Horwell makes a return to New York Fashion Week, captivating the city with her signature execution of sexy elegance. An experimental play on mixed materials and pops of color elevates Hardware LDN's quintessential style of grunge and glamour.

Hardware LDN Debuts Fall/Winter 2022 Collection

NEW HAVEN, Conn., Feb. 3, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports

LOS ANGELES--(BUSINESS WIRE)--Global Coalition for Adaptive Research (GCAR) announces key updates on GBM AGILE phase 2-3 adaptive platform trial for patients with glioblastoma.

Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma

NEW HAVEN, Conn. and LEUVEN, Belgium, Jan. 10, 2022 /PRNewswire/ -- Biohaven Therapeutics Ltd.

Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain

News for Biohaven Pharmaceutical Hld Stock (BHVN)